

Comparison of the materno-fetal transfer of fifteen structurally related bisphenol analogues using an ex vivo human placental perfusion model

Clémence Gely, Marlène Z. Lacroix, Mathieu Morin, Christophe Vayssiere,

Véronique V. Gayrard-Troy, Nicole Picard-Hagen

▶ To cite this version:

Clémence Gely, Marlène Z. Lacroix, Mathieu Morin, Christophe Vayssiere, Véronique V. Gayrard-Troy, et al.. Comparison of the materno-fetal transfer of fifteen structurally related bisphenol analogues using an ex vivo human placental perfusion model. Chemosphere, 2021, 276, pp.130213. 10.1016/j.chemosphere.2021.130213. hal-03196053

HAL Id: hal-03196053 https://hal.inrae.fr/hal-03196053

Submitted on 24 Apr 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S0045653521006822 Manuscript_178dcb8387f6e2be45631e59121d874f

| 1 | Comparison of the materno-fetal transfer of fifteen structurally related bisphenol |
|----|--|
| 2 | analogues using an <i>ex vivo</i> human placental perfusion model |
| 3 | Clémence A. Gély ^{1,2} , Marlène Z. Lacroix ² , Mathieu Morin ³ , Christophe Vayssière ^{3,4} , Véronique |
| 4 | Gayrard ¹ , Nicole Picard-Hagen ¹ |
| 5 | ¹ ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRAE, ENVT, |
| 6 | INP-Purpan, UPS, Toulouse, France |
| 7 | ² INTHERES, Université de Toulouse, INRAE, ENVT, Toulouse, France |
| 8 | ³ Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, |
| 9 | Toulouse, France |
| 10 | 4UMR 1027 INSERM, Team SPHERE, Université de Toulouse, France. |
| 11 | |
| 12 | Véronique Gayrard: veronique.gayrard@envt.fr; Clémence Gély: clemence.gely@inrae.fr ; Marlène |
| 13 | Z. Lacroix: marlene.lacroix@envt.fr, Mathieu Morin: morin.m@chu-toulouse.fr; Nicole Picard- |
| 14 | Hagen: nicole.hagen@envt.fr; Christophe Vayssière: vayssiere.c@chu-toulouse.fr. |
| 15 | Corresponding author: |
| 16 | Email: nicole.hagen@envt.fr |
| 17 | UMR1331 Toxalim |
| 18 | Ecole Nationale Vétérinaire de Toulouse |
| 19 | 23 chemin des Capelles, BP 87614 |
| 20 | 31076 Toulouse cedex 3 |
| 21 | France |

- 22 Competing financial interests: The authors declare that they have no actual or potential
- 23 competing financial interests¹

24

¹ Abbreviations

BPS: Bisphenol S; BPA: Bisphenol A; BPE: Bisphenol E; 3-3BPA: 2,2-Bis(4-hydroxy-3methylphenyl)propane (3-3BPA); BPB: Bisphenol B; BPC: Bis(4-hydroxyphenyl)-2,2dichloroethylene; BPBP: Bisphenol BP; BPF: Bisphenol F; BPFL: Bisphenol FL; BPZ: Bisphenol Z; BP4-4: 4,4'-Dihydroxybiphenyl; BPAP: Bisphenol AP; BPAF: Bisphenol AF; BPP: Bisphenol P; BPM: Bisphenol M; LOQ: limit of quantification.

BSA: Bovine Serum Albumin; ESI- : negative electrospray; IS: Internal Standard; MRM: Multiple Reaction Monitoring; OAT: Organic Anion Transporter; QC: Quality Control; RCR: Relative Concentration Residuals; UHPLC-MS/MS: Ultra-High-Performance Liquid Chromatography method coupled to tandem mass spectrometry¹

25 Highlights

• The efficiency of placental transport differs greatly between bisphenols.

• BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA cross placenta by simple diffusion.

• Materno-fetal transfer of BPFL and BPS is very limited.

29 Abstract

30 Regulatory measures and public concerns regarding bisphenol A (BPA) have led to its 31 replacement by a variety of alternatives in consumer products. Due to their structural similarity to 32 BPA, these alternatives are under surveillance, however, for potential endocrine disruption. 33 Understanding the materno-fetal transfer of these BPA-related alternatives across the placenta is 34 therefore crucial to assess prenatal exposure risks.

The objective of the study was to assess and compare the placental transfer of a set of 15 selected bisphenols (BPs) (BP 4-4, BPA, BPAF, BPAP, 3-3 BPA, BPB, BPBP, BPC, BPE, BPF, BPFL, BPM, BPP, BPS and BPZ) using the *ex vivo* human placental perfusion model.

38 The UPLC-MS/MS method for simultaneous quantification of these BPs in perfusion media, within 39 a concentration range of 0.003 to 5 μ M, was able to measure placenta transfer rates as low as 0.6 40 % to 4 %. Despite their structural similarities, these BPs differed greatly in placental transport 41 efficiency. The placental transfer rates of BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA were 42 similar to that of antipyrine, indicating that their main transport mechanism was passive diffusion. 43 By contrast, the placental transfer rates of BPFL and BPS were very limited, and intermediate for 44 BPBP, BPZ, BPC, BPM, BPP and BPAF, suggesting weak diffusional permeability and/or that their passage might involve efflux transport. These placental transfer data will be particularly useful for 45 46 predicting the fetal exposure of this important class of emerging contaminants.

47

48 *Keywords:* bisphenols, human placental transfer, mixture, endocrine disruptor, Liquid
49 chromatography, Mass spectrometry

50 Introduction

51 Serious concerns regarding widespread human exposure to Bisphenol A (BPA) and its adverse health effects have led to the ban or restriction of BPA production and use in many countries, 52 prompting the development of structural analogues to replace BPA in a variety of industrial 53 54 products (Chen et al., 2016; Liao and Kannan, 2013; Yang et al., 2014). The list of such BP 55 alternatives is still growing and over 20 BPs, including bisphenols AF, AP, B, F, P, S and Z, are 56 used as monomers in the manufacture of epoxy resin and polycarbonate for many consumer 57 products, such as foodstuffs, personal care products, and paper products (Chen et al., 2016; González et al., 2020; Liao and Kannan, 2014). Given the environmental ubiquity of these BPs, 58 59 humans are constantly being exposed via dietary intake and daily dermal contact with such products. The increased frequency of detection of BPA alternatives in urine indicates the reality of 60 61 BPA substitution (Frederiksen et al., 2020; Gyllenhammar et al., 2017; Husøy et al., 2019; Lehmler 62 et al., 2018; Lucarini et al., 2020; Philips et al., 2018; Ye et al., 2015). In particular, a human 63 biomonitoring study revealed the presence of 7 BPs (detection rate: BPA 93%, BPS 89%, BPF 12%, BPP 39%, BPZ 18%, BPAF 66% and BPAP 44%) in 283 urine samples collected from 64 65 children in southern China (Chen et al., 2018).

66 However, little is known about the potential adverse effects of these emerging BPA substitutes and 67 most of the toxicological information is limited to their endocrine disruption potential. Like BPA, 68 these structurally similar phenolic compounds seem to affect hormonal systems (Chen et al., 2016; 69 Kojima et al., 2019; Moreman et al., 2017; Pelch et al., 2019; Rochester and Bolden, 2015; 70 Rosenmai et al., 2014; Siracusa et al., 2018; Usman and Ahmad, 2016; Zhang et al., 2018). The 71 developmental effects of some BPs analogues in mammals, mainly rodents, have been 72 documented in a recent literature review (Pelch et al., 2019). Most studies have only investigated a 73 single BPA analogue, such as BPS, BPAF, BPF or BPE, thereby precluding direct comparisons 74 between them. In addition, the endpoints evaluated in these studies were diverse and included altered hormonal signaling and reproduction (Shi et al. 2018), disruption of mammary gland 75 76 development (Tucker et al., 2018), behavioral changes (Catanese and Vandenberg, 2016) and metabolic disorder (Mustieles et al., 2020). For example, a study of prenatal *in vivo* exposure to
BPS and BPAF showed that such exposure affects the mammary gland of the developing fetus
(Tucker et al., 2018). Altogether, these data highlight the vulnerability of the developmental period
to exposure to these emerging BPs.

81 Data on human biomonitoring of BP analogues in maternal-cord blood samples remain limited, with 82 most studies focused on only 2 or 3 analogues (Ihde et al., 2018; Liu et al., 2017; Pan et al., 2020; 83 Zhang et al., 2020). Several alternative BPs, including BPS, BPAF, BPE, BPF and BPAP have 84 frequently been detected in the human maternal-fetal-placental unit (Pan et al., 2020), indicating that such contaminants can across the placental barrier. Given their structural diversity, the harmful 85 86 consequences of BPA substitution for fetal health may be exacerbated if the physicochemical 87 properties of these analogues promote their placental transfer, and thus increase fetal exposure. 88 Understanding the materno-fetal transfer of these BPA alternatives across the placenta is therefore 89 crucial for assessing prenatal exposure risks.

90 To that end, the ex vivo perfused human placental cotyledon model, which allows reproduction of 91 the conditions of the third trimester of pregnancy, is the method of choice for studying human 92 placental transfer (Hutson et al., 2011). This model had already been used to quantify the 93 transplacental transfer of BPA (Corbel et al., 2014) and BPS (Grandin et al., 2019) and was 94 therefore used here to investigate the materno-fetal placental transfer of fifteen BPs. We focused 95 on bisphenol 4-4, bisphenol A, bisphenol AF, bisphenol AP, 3-3 bisphenol A, bisphenol B, 96 bisphenol BP, bisphenol C, bisphenol E, bisphenol F, bisphenol FL, bisphenol M, bisphenol P, 97 bisphenol S, and bisphenol Z (Figure 1), because of their occurrence in foodstuffs (Caballero-98 Casero et al., 2016; Liao and Kannan, 2013), their volume of production ("Search for Chemicals -99 ECHA,"), their presence in human urine (Chen et al., 2018) and their structural diversity.

We chose a cocktail approach because the placenta perfusion method remains a time-consuming experimental method that required some logistic and technical challenges. We first developed and validated an ultra-high-performance liquid chromatography method coupled to tandem mass spectrometry to assay all fifteen BPs simultaneously. To check that the combination of 15 BPs did not interfere with the placental transfer mechanism, we compared the maternal-fetal placental indices of BPA and BPS evaluated with this cocktail approach to those previously determined for these compounds perfused individually using the same model (Corbel et al., 2014; Grandin et al., 2019). This approach, by allowing comparison of the values obtained for a key parameter, placental clearance, should provide new insights for understanding fetal BPs exposure and assessing the hazards of BPA substitution in vulnerable populations, such as the developing fetus.

110

111 1. Material and methods

112 The study was designed to evaluate the simultaneous placental transfer of fifteen BPs in the 113 maternal-fetal direction.

114 1.1 Chemicals

115 Bisphenol S (BPS) (purity \geq 98%), Bisphenol A (BPA) (purity \geq 99%), Bisphenol E (BPE) (purity \geq 116 98%), 2,2-Bis(4-hydroxy-3-methylphenyl)propane (3-3BPA) (purity \geq 97%), Bisphenol B (BPB) 117 (purity \geq 98%), Bis(4-hydroxyphenyl)-2,2-dichloroethylene (BPC) (purity \geq 98%), Bisphenol BP 118 (BPBP)(purity \geq 98%), Bisphenol F (BPF) (purity \geq 98%), Bisphenol FL (BPFL) (purity \geq 97%), 119 Bisphenol Z (BPZ) (purity \geq 98%), 4,4'-Dihydroxybiphenyl (BP4-4) (purity \geq 97%), Bisphenol AP 120 (BPAP) (purity \geq 99%), Bisphenol AF (BPAF) (purity \geq 97%), Bisphenol P (BPP) (purity \geq 98%), 121 Bisphenol M (BPM) (purity \geq 99%) (Figure 1) and antipyrine (purity \geq 98%) were purchased from 122 Sigma-Aldrich (Saint-Louis, Missouri, USA).





124 Figure 1: Molecular structures of the fifteen BPs

Six isotopes-labeled standards, namely, BPAF-d4 (purity \ge 98%), BPAP-d5 (purity \ge 97.5%), BPPd16 (purity \ge 98%), BPS-d8 (purity \ge 97%), and BPA¹³C₁₂ (purity \ge 98%), used as internal standards, were purchased from Toronto Research Chemicals (Toronto Canada). Methanol and Acetonitrile were LC/MS quality and purchased from Fisher Scientific (Illkirch, France) and acetone was LC quality purchased from Sigma-Aldrich (Saint-Louis, Missouri, USA).

130 All BPs, except BPBP, were dissolved in ethanol at a concentration of 150mM. BPBP was 131 dissolved at 30mM, due to its weak solubility. A solution containing all fifteen BPs was prepared at 132 the same concentration of 7.5mM for each BP, except BPBP (concentration of 1.5mM). The 133 solutions were stored at -20 °C until use. Bovine serum albumin (BSA, Fraction V, purity 100%, 134 Aviva Systems Biology, San Diego, USA) and Earle's Balanced Salt solution were purchased from 135 United States Biological (Salem, MA 01970, United-States). The materials for placental perfusion, 136 including the materials used to prepare solutions, sampling, processing and analysis, were in glass 137 or BPA- and BPS-free plastic containers and the absence of leaching of BPs from the tubing was 138 verified.

The absence of binding to the perfusion equipment was checked by comparing the BPs concentrations in the maternal reservoir and in the maternal perfusate circulating in the tubing without the cotyledon (mean ratios between 93 and 103% for the BPs).

142 1.2 Placental perfusion

Placentas (519 \pm 113g) were collected from HIV-seronegative women with normal pregnancies following vaginal (n = 1) or caesarean (n = 4) delivery in the CHU Paule de Viguier, Toulouse, France. The study received institutional approval (DC-2016-2694) and each patient gave written informed consent to participate in the study.

147 Collected placentas were perfused in an open double circuit as previously described (Corbel et al., 148 2014; Grandin et al., 2019). Perfusion experiments were started within 30 min after delivery. 149 Briefly, after visual confirmation of the vascular integrity of both the maternal and fetal sides, a 150 distal branch of a fetal artery and the associated vein supplying a peripheral cotyledon, were

151 cannulated (Microtube Tygon S54HL, Saint Gobain, Courbevoie, France). The balance between 152 arterial and venous fetal flows was evaluated and placentas with evidence of vascular leakage 153 were discarded (Karttunen et al., 2015). On the maternal side, the perfused area progressively 154 whitened, which allowed visualization of the chosen cotyledon. The cotyledon was placed in the perfusion chamber and maintained at 37°C, with the maternal side upward. Perfusion on the 155 156 maternal side was subsequently initiated by inserting two catheters into the intervillous space. The 157 fetal and maternal flows were 6 and 12 ml/min, respectively, and the perfusion length was 90 min. 158 The pH was continuously adjusted throughout the perfusion to 7.41 \pm 0.022 and 7.23 \pm 0.025 for 159 the maternal and fetal perfusion media, respectively. The balance between arterial and venous 160 fetal flows and pressures (between 40 and 60 mm Hg) were monitored throughout the experiment 161 to control the integrity and functionality of the perfusion. Earle medium supplemented with 25 g/L 162 bovine serum albumin (BSA) at 37 °C was used to reflect the physiological plasma protein 163 concentrations at late pregnancy (Larsson et al., 2008). Indeed, some BPs (BPA, BPS, BPF, BPE, 164 BPB, BPM and BPAF) have been shown to bind to plasma albumin (Grumetto, 2019; Luo et al., 165 2016; Wang et al., 2014; Yang et al., 2017). BSA was used because of its 76.5 % sequence 166 homology with human serum albumin. Antipyrine (20 µg/mL), a reference substance for control of passive diffusion and barrier integrity (Karttunen et al., 2015), and the BPs mixture, were added to 167 168 the maternal reservoir to study materno-fetal transfer. Because the placental transfer of BPS had 169 been previously reported to be low (Grandin et al., 2019), all BPs (except the weakly soluble 170 BPBP) were used at a final nominal concentration of 5 μ M (1 μ M for BPBP) to ensure their 171 effective detection in the fetal compartment.

172 Control samples (1 mL) were collected from the fetal and maternal inflow reservoirs before the 173 addition of antipyrine and BPs and from the maternal reservoir after simultaneously adding BPs 174 and antipyrine solutions (time 0) and at 30, 60 and 90 min. During the perfusion, fetal exudates 175 were collected every 5 min and their volumes measured. Maternal exudates were collected 176 immediately after adding the test molecules and every 30 min up to 90 min. At the end of the 177 perfusion, the isolated cotyledon was rinsed with phosphate-buffered saline (pH 7.4) for 15 min.

This washing solution was collected. All samples were immediately chilled in ice and centrifuged for 10 min at 3000g and 4 °C to discard placental cells and the supernatant was collected and stored at -20 °C until assayed.

181 1.3 Antipyrine assay

182 Antipyrine concentrations in the perfusion medium were determined by UHPLC coupled with UV 183 detection. Briefly, antipyrine was extracted from the perfusion medium (100 µL of sample) by 184 adding 200µL of 5 % trichloroacetic acid. After mixing and centrifuging (20000 g, 10 min and 4°C), 185 samples were eluted on a C18 column at 0.3 mL/min and 40°C using H₂O / acetonitrile gradient 186 elution with UV detection set at 250 nm. The calibration curve ranged from 0.5 to 50 µg/mL. Data 187 were fitted using a linear model with 1/X (X = concentration) as weighting factor. Blank samples 188 were used to check the absence of contamination during the assays. Accuracy ranged from 87% to 189 103% and the intra- and inter-day coefficients of variation for three concentration levels (0.8, 8 and 190 $30 \mu g/mL$) were below 11%. The limit of quantification (LOQ) was validated at 0.5 $\mu g/mL$.

191 1.4 Simultaneous quantification of 15 bisphenols in placenta perfusion media

192 1.4.1 Analytical conditions

The materno-fetal transfer rates of BPA (Corbel et al., 2014) and BPS (Grandin et al., 2019) previously evaluated on the same perfused placenta model were on average 29 and 3.18 %, respectively. Our objective was to develop a simultaneous assay, without dilution, of the fifteen BPs both in the maternal reservoir and in the fetal outflow perfusate, i.e. with a wide concentration range between 0.05 and 5 μ M so as to be able to evaluate materno-fetal transfer rates of BPs ranging between 1% and 40-50%.

Samples were assayed by ultra-high performance liquid chromatography coupled to tandem mass spectrometry (Acquity-2D UPLC® Xevo® TQ, Waters, Milford, MA, USA) using the methods previously described by Grandin et al., 2017 and Lacroix et al., 2011. Briefly, BPs were extracted from the perfusion medium (100µL of sample) by adding 200µL of acetone containing internal

standards (100 ng/mL). Samples were mixed for 1 min at 10°C and 1400 rpm and centrifuged at 204 20000 g and 4°C for 10 min. Then, 200 μ L of supernatant were evaporated to near dryness under 205 nitrogen at 50°C and reconstituted with 200 μ L of methanol/H₂O: 50/50 (v/v). The BPs were 206 separated on a Raptor Biphenyl column (100 x 2.1 mm; 2.7 μ m, Restek) at 0.3 mL/min and 40°C 207 using H₂O/ methanol gradient elution.

Analytes were detected in negative electrospray (ESI⁻) using multiple reaction monitoring (MRM) mode. The MRM transitions of BPs and IS with their respective cone voltages and collision energies are given in Supplementary Material Table S1.

211 1.4.2 Validation procedure

The performance of the method was evaluated according to the European Medicine Agency Guidelines (European Medicine Agency, 2011) for bioanalytical method validation in terms of linearity, intra-day and inter-day repeatability, and sensitivity. Selectivity was tested by comparing five blank perfused media chromatograms with chromatograms at the limits of quantification (LOQ). The LOQs were defined as the lowest concentrations of the calibration curve that could be quantified with less than 20% coefficient of variation (CV%), precision and within an accuracy range of 80–120%.

219 For each BP calibration curve, both simple (Y = aX + b) and quadratic $(Y = aX^2 + bX + c)$ models 220 were tested after applying appropriate weighting: 1, 1/X and $1/X^2$ (X = nominal concentration). 221 Three approaches were adopted to assess the linearity of the calibration curve: (1) calculation of 222 the relative concentration residuals (RCR%) between the nominal concentration and the 223 concentration obtained with the model, which should be lower than ± 15% (except at the LOQ, ± 224 20%), (2) visual inspection of the residual distribution which should be randomized around the 225 mean and (3) application of a lack-of-fit test to check the goodness-of-fit of the model. Within-day 226 and between-day precisions and accuracies for each BP were calculated on three different days 227 and with six replicates of QC samples at four concentration levels (3, 30, 300 and 1500 ng/mL).

228 1.5 Placental transfer parameters

Perfusions in the materno-fetal direction were validated if the transfer rate of antipyrine was above the generally accepted threshold of 20% (Challier et al., 1983; Gavard et al., 2009; Schneider et al., 1972) and remained stable throughout the perfusion. Only the concentrations at steady state for antipyrine and all BPs were used to calculate the transfer rate and the clearance index.

As previously described (Corbel et al., 2014; Grandin et al., 2019), the transfer rate was calculated for each steady state time point as the ratio between concentrations in the fetal compartment to concentrations in the maternal compartment. To take the inter placenta variability into account, the clearance index *i.e.* the ratio of the transfer rate of each bisphenol to that of antipyrine, was determined.

The mass balance for antipyrine and the 15 BPs was calculated as the ratio of the sum of the quantities of substrate in all the maternal and fetal exudate media and PBS washings to the measured amount of substrate in the maternal reservoir, as previously described (Corbel et al., 2014).

242 1.6 Statistical analysis

243 First, the materno-fetal placenta transfer rate of each bisphenol was compared with that of 244 antipyrine using a Dunnett's multiple comparisons test, with a confidence level of 0.95. Two groups 245 of bisphenols had been identified in a first test: one group containing bisphenols with a transfer rate 246 non significantly different to that of antipyrine and a second group containing bisphenols with a 247 significantly lower transfer rate than that of antipyrine. For each group of bisphenols, the placental 248 clearance indices were compared using an ANOVA followed by a post-hoc Tukey test with a 249 confidence level of 0.95. The statistical analyses were done using the R® software (R 250 development core team, 2009).

251 *2. Results*

252 2.1 Performance of the method for the simultaneous quantification of 15 bisphenols

253 The selectivity of the method was evaluated by comparing the areas of the BPs on five blank 254 samples to the areas at the LOQs. The areas in blank samples were below 20% of that of the 255 LOQs for all BPs except BPAF (29 %) and BPS (43 %). Indeed, BPS was systematically detected 256 in blank media but the areas were always at least two-fold lower than that of their LOQ. However, 257 the method remains suitable for the assessment of BPs placenta transfer since BPs contamination 258 was monitored by injecting blank medium during the sample assays. The LOQs were validated at 1 259 ng/mL for BPAF and BPAP, 5 ng/mL for BP4-4, BPF, BPE, BPA, BPB, BPZ, BPM, BPFL, BPBP, 260 10 ng/mL for BPS and 50 ng/mL for 3-3BPA, BPC and BPP, with intra-day CVs below 21 % and 261 accuracies within 83-119%. Intra- and inter-day precisions were below 22% with accuracy ranging 262 from 85% to 117% for all BPs (Table 1). The calibration curve ranges were established from the 263 BP LOQs up to 2000 ng/mL to ensure placental transfer rate measurements between 1 and 50 % without requiring sample dilutions. The method was therefore suitable for the simultaneous 264 265 quantification of fifteen BPs in both the maternal reservoir and the fetal outflow perfusate.

| Compound | | BP4-4 | BPS | BPF | BPE | BPA | BPAF | BPB | 3-3BPA | BPZ | BPC | BPAP | BPP | BPM | BPFL | BPBP |
|--------------------|-----------------------|-------------------------|----------------------------|----------------------------|---------------|------------|----------------------------|-------------------------|---------------|---------------|---------------|---------------|----------------------------|----------------------------|-------------------------------|-------------------------------|
| Internal Standard | | BPA13C12 | BPSd8 | BPAF- d4 | BPAF- d4 | BPA13C12 | BPAF- d4 | BPA13C12 | BPAP- d5 | BPAP- d5 | BPAF- d4 | BPAP- d5 | BPP- d16 | BPAP-d5 | BPAP-d5 | BPAP-d5 |
| Model | | Linear 1/X ² | Linear 1/X ² | Linear 1/X ² | Linear 1/X | Linear 1/X | Linear 1/X ² | Linear 1/X ² | Linear 1/X | Linear 1/X | Linear 1/X | Linear 1/X | Linear 1/X ² | Quadratic 1/X ² | Quadratic 1/X ² | Quadratic 1/X ² |
| LOQ (ng/mL) | | 5 | 10 | 5 | 5 | 5 | 1 | 5 | 50 | 5 | 50 | 1 | 50 | 5 | 5 | 5 |
| CV intra- day % | QC = 3 ng/mL | - | - | - | - | - | 7 | - | - | - | - | 12 | - | - | - | - |
| | QC = 30 ng/mL | 14 | 4 | 16 | 13 | 18 | 3 | 10 | - | 9 | - | 5 | - | 15 | 9 | 15 |
| | QC = 300 ng/mL | 12 | 3 | 13 | 8 | 11 | 4 | 7 | 9 | 4 | 7 | 2 | 13 | 9 | 8 | 5 |
| | QC = 1500 ng/mL | 14 | 2 | 10 | 11 | 9 | 11 | 11 | 8 | 4 | 4 | 3 | 15 | 11 | 14 | 13 |
| CV inter- day % | QC = 3 ng/mL | - | - | - | - | - | 6 | - | - | - | - | 14 | - | - | - | - |
| | QC = 30 ng/mL | 14 | 4 | 15 | 13 | 22 | 3 | 16 | - | 11 | - | 8 | - | 18 | 21 | 15 |
| | QC = 300 ng/mL | 15 | 6 | 14 | 7 | 15 | 4 | 12 | 14 | 4 | 17 | 4 | 16 | 15 | 10 | 9 |
| | QC = 1500 ng/mL | 14 | 4 | 14 | 16 | 14 | 6 | 12 | 16 | 4 | 18 | 3 | 12 | 18 | 15 | 14 |
| | QC = 3 ng/mL | - | - | - | - | - | 105 | - | - | - | - | 109 | - | - | - | - |
| | QC = 30 ng/mL | 97 | 100 | 98 | 95 | 89 | 101 | 109 | - | 99 | - | 100 | - | 117 | 106 | 112 |
| Accuracy % | QC = 300 ng/mL | 105 | 102 | 106 | 106 | 96 | 108 | 112 | 103 | 104 | 90 | 101 | 102 | 108 | 113 | 113 |
| | QC = 1500 ng/mL | 114 | 94 | 109 | 97 | 92 | 109 | 97 | 103 | 99 | 85 | 99 | 102 | 90 | 102 | 92 |
| LOQ | CV intra- day % | 12% | 7% | 15% | 7% | 15% | 11% | 11% | 9% | 13% | 17% | 21% | 15% | 11% | 1% | 5% |
| | Accuracy % | 114% | 105% | 113% | 99% | 106% | 109% | 100% | 119% | 116% | 94% | 111% | 108% | 83% | 94% | 103% |
| Table | 1: \ | /alidation | resu | lts f | or t | the sim | ultaned | ous qua | Intificatio | on o | f 15 | 5 bis | phenols | in | placenta | mediu |

268 2.2 Placental transfer of the mixture of 15 bisphenols

269 The overall mean antipyrine transfer rate, for all the validated perfusions (n=5), was $31.7 \pm 12.6\%$ 270 and conforms closely to values reported previously (Corbel et al., 2014; Grandin et al., 2019; 271 Gavard et al., 2009). The wet weight of the perfused cotyledons was 27 ± 4 g (n=3). The average flow rates were 12.5±1.9 mL/min in the maternal circulation and 5.3±0.7 mL/min in the fetal 272 273 circulation and remained stable throughout the perfusion. No BPs and no antipyrine were detected 274 at levels above the LOQs in control perfusion medium samples collected from the maternal and 275 fetal exudates before adding the compounds. The mean recovery for all BPs was not significantly 276 different from that of antipyrine (89±6.2%, range 86%-91%), except for BPE (77 ± 6 %, range:70-84%, p=0.03, Dunnett test). This incomplete recovery of BPE could be explained by BPE placental 277 278 metabolism. But the absence of signal corresponding to the MRM transitions of the 15 bisphenol 279 mono-glucuronides confirms the very limited in vitro placental metabolism in this open non-280 recirculating perfusion model.

Table 2 summarizes the materno-fetal placental transfer rate and clearance indices of the perfused mixture of fifteen BPs (at the concentration of 5 μ M, except for BPBP, 1 μ M) and antipyrine (at the concentration of 20 μ M).

| | n=5 | Antipyrine | BPA | BPS | BPF | BPAF | BPB | BPE | BPC | BP4-4 | 13-3BPA | BPAP | BPBP | BPP | BPM | BPZ | BPFL |
|---|------|------------|-------|-------|-------|-------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-------|-------|
| Transfer rate ^a (%) | Mean | 31.68 | 25.70 | 2.45 | 22.52 | 16.38 | 26.45 | 21.52 | 12.25 | 21.13 | 22.86 | 18.10 | 7.99 | 14.68 | 14.48 | 9.87 | 1.98 |
| | SD | 12.64 | 9.85 | 0.77 | 11.10 | 5.95 | 9.11 | 8.86 | 4.55 | 9.27 | 8.75 | 7.15 | 2.66 | 6.68 | 7.34 | 3.94 | 0.70 |
| Discentel clearance ^b (ml. (min) | Mean | 1.671 | 1.345 | 0.129 | 1.164 | 0.857 | 1.387 | 1.115 | 0.640 | 1.105 | 5 1.196 | 0.946 | 0.420 | 0.770 | 0.763 | 0.518 | 0.105 |
| | SD | 0.614 | 0.467 | 0.039 | 0.518 | 0.284 | 0.436 | 0.401 | 0.222 | 0.455 | 0.414 | 0.341 | 0.135 | 0.326 | 0.367 | 0.195 | 0.039 |
| | Mean | - | 0.813 | 0.079 | 0.696 | 0.522 | 0.842 | 0.685 | 0.392 | 0.663 | 0.722 | 0.570 | 0.257 | 0.451 | 0.444 | 0.318 | 0.065 |
| | SD | - | 0.063 | 0.017 | 0.144 | 0.072 | 0.079 | 0.158 | 0.074 | 0.136 | 0.070 | 0.062 | 0.046 | 0.047 | 0.148 | 0.090 | 0.020 |

285

Table 2: Materno-fetal parameters (clearance, transfer rate and clearance index) of 15 bisphenols perfused as a cocktail. "The ratio of the 286 287 concentration in the receiving compartment to the concentration in the entrance compartment expressed as a percentage. ^bThe concentration in the 288 receiving compartment multiplied by its flow rate to the concentration in the entrance compartment. "The ratio of the transfer rate of each bisphenol to 289 that

of

antipyrine

290 Despite their similar phenolic structures, these BPs showed a considerable range of placental 291 transfer rates. The transfer rates of BP4-4 (21.13 ± 9.27 %), BPAP (18.10 ± 7.15 %), BPE (21.52 ± 292 8.86 %), BPF (22.52 ± 11.10 %), 3-3BPA (22.86 ± 8.75 %), BPB (26.45 ± 9.11 %) and BPA (25.70 \pm 9.85 %) were not significantly different to that of freely diffusible antipyrine (31.68 \pm 12.64%). By 293 294 contrast, the placental transfer rates of the others were significantly lower than that of antipyrine 295 (p < 0.05, Dunnett's multiple comparisons test) and ranged from 7-16% for BPBP (7.99 ± 2.66%), 296 BPZ (9.87 ± 3.94%), BPC (12.25 ± 4.55%), BPM (14.48 ± 7.34%), BPP (14.68 ± 6.68%) and BPAF 297 (16.38 ± 5.95%). In addition, the BPFL and BPS placental transfer rates were 10 and 13-fold lower 298 than that of BPA, *i.e.*, 1.98 ± 0.70 % and 2.45 ± 0.77 %, respectively.

Figure 2 depicts the individual values and mean ± SD of the BP clearance indices. The clearance indices for BPs ranged from 0.065 to 0.842. In group 1, the clearance indices were very close and only BPA and BPB had a significantly higher clearance index than BPAP (Tukey test). In group 2, the clearance indices gradually decreased from 0.522 (BPAF) to 0.257 (BPBP), whereas the clearance indices of BPFL (0.065) and BPS (0.079) were significantly lower than those of all BPs in Group 2. The BPBP clearance index was significantly lower than those of BPM, BPP and BPAF and the BPAF clearance index was significantly higher than that of BPZ.



significantly from that of antipyrine. Group 2 consists of bisphenols with transfer rates that differed significantly from that of antipyrine.

- 307 Figure 2: Clearance indices of the 15 BPs (individual values (x) and mean ± SD), corresponding to
- 308 the ratio of BP-studied placental transfer rate divided by the antipyrine transfer rate.

309 *3. Discussion*

Prenatal exposure to BPs may result in adverse effects on sensitive developmental processes. The scarcity of data concerning exposure of the human fetus to BPs analogues highlights the urgent need for a better understanding of the maternal-fetal-placental exchanges of these emerging structurally-related BPs.

In the present study, the *ex vivo* perfusion model of the human term placenta was used to examine the placental passage of 15 structurally related BPs. A method for the simultaneous quantification of 15 BPs analogues in the perfusion media was developed in UHPLC-MS/MS with performance fulfilling the acceptability criteria recommended in the EMA guidelines, in terms of sensitivity, precision and accuracy (European Medicines Agency, 2011). This method is suitable for quantifying low materno-fetal placental transfer rates within 0.6-4% depending on the BPs.

Antipyrine, a free passive diffusion reference which is not bound to plasma proteins, was used as a reference substance to assess the transfer rates of lipid-soluble xenobiotics (Ala-Kokko et al., 2000). The antipyrine clearances observed in this study (1.06-2.34 mL/min) were close to values reported previously, 2.24±0.68 mL/min and 1.83±0.619 mL/min, respectively (Corbel et al., 2014; Grandin et al., 2019). The clearance of each BP was expressed as a fraction of the antipyrine clearance (clearance index) to overcome inter-placental variability (Challier, 1985), and allow comparisons between different BPs and different experiments.

The BPA and BPS clearance indices (0.813±0.063 and 0.079±0.017) evaluated here with a combination of fifteen BPs, did not differ from those determined previously with the same compounds perfused separately (0.813±0.13 and 0.0852±0.0515, respectively, (Corbel et al., 2014; Grandin et al., 2019), suggesting that the combination of 15 BPs did not interfere with the placental transfer mechanism and thus validated our cocktail approach.

332 Despite the structural similarities of these 15 BPs, the clearance indices for the current data set 333 ranged from 0.065 for BPFL to 0.842 for BPB, indicating considerable differences in the efficiency 334 of BP transport between BPs. The placental transfer rates of BP4-4, BPAP, BPE, BPF, 3-3BPA,

BPB, BPA were similar to that of antipyrine, suggesting that exchange of these bisphenols across the placenta mainly involves passive diffusion and is solely limited by the placental blood flow. By contrast, the placental transfer rates for BPFL and BPS were very limited, and intermediate for BPBP, BPZ, BPC, BPM, BPP and BPAF suggesting that the placental transfer of these BPs does not rely solely on weak diffusional permeability but might involve differentially active transport. However, considering the high doses of BPs used, a saturation of the placental transfer cannot be ruled out.

342 In agreement with these findings, previous comparative toxicokinetic results in a pregnant sheep 343 model showed that the materno-fetal transfer of BPS was ten-fold lower than that of BPA 344 (Gauderat et al., 2017; Grandin et al., 2018) and that the feto-maternal total concentrations ratio of 345 BPS was lower than those of BPF and BPA after a single subcutaneous administration of BPS or a 346 mixture of BPA, BPS and BPF (Gingrich et al., 2019). Moreover, in a recent prospective birth 347 cohort (Zhang et al., 2020), the ratio between umbilical cord and maternal total plasma 348 concentrations of BPS was lower (1.11 in 11 pairs) than the ratios for BPA (1.94, n=73) and BPAF 349 (3.26, n=22), which is consistent with a lower placental passage of this BP analogue. However, the 350 human isolated cotyledon model, unlike the *in vivo* model, does not incorporate those nonplacental 351 toxicokinetic factors that determine fetal exposure, such as maternal and fetal metabolism. Thus, it 352 was shown in the pregnant sheep model that despite the low materno-fetal placental transfer of 353 BPS, the accumulation of BPS in the fetal compartment after repeated maternal exposure led to 354 chronic fetal exposure to BPS in a range of concentrations similar to those obtained for BPA 355 (Grandin et al., 2018). Another limitation imposed by this model is that the present results refer to 356 placenta at term and cannot necessarily be extrapolated to earlier stages of gestation. However, 357 due to the placental thickness, the maximal uterine flow and the decrease of certain efflux transporters such as P-glycoprotein at term (Ceckova-Novotna et al., 2006; Joshi et al., 2016), the 358 359 materno-fetal placental transfer rate at term may be considered as higher than at earlier 360 gestational ages (Syme et al., 2004).

361 The placental transfer process may depend on the physicochemical and molecular properties of 362 BPs, such as molecular size, lipophilicity (LogP), degree of ionization (pKa) and hydrogen-binding 363 capacity (Syme et al., 2004, Gedeon and Koren, 2006, Giaginis et al. 2009). In general, neutral 364 compounds with a molecular weight below 600 Da, high lipid solubility (LogP>1) and few hydrogen 365 bonding sites have a high potential to freely diffuse across the placenta (Audus, 1999; Pacifici and 366 Nottoli, 1995). Thus, the physicochemical properties of these 15 BPs (LogP within 2-7, pKa close 367 to 8.5-9 and MW below 600 Da) would imply that their potential passive diffusion across the 368 placenta would be high (Table 4). However, this is only true for seven BPs (BPAP, BP4-4, BPE, 369 BPF, 3-3BPA, BPA and BPB). By contrast, the restricted transplacental permeability of BPBP, 370 BPZ, BPC, BPM, BPP, BPAF, and, notably of BPS and BPFL, cannot be predicted solely from their 371 physicochemical properties (Table 3).

| | Molecular weight (Da) ^a | pKaª acidity constant | log P ^b partition coefficient | percent unbound to plasma proteins (Grumetto, 2019) | Clearance indices° (mean ± SD) |
|--------|--|-----------------------------|--|--|-----------------------------------|
| BPFL | 350.13 | 9.14 | 5.59 | | 0.065 ± 0.020 |
| BPS | 250.03 | 8.44 | 2.15 | 13.23 | 0.079 ± 0.017 |
| BPBP | 352.15 | 9.21 | 6.02 | | 0.257 ± 0.046 |
| BPZ | 268.15 | 9.45 | 5.00 | | 0.318 ± 0.090 |
| BPC | 280.01 | 9.23 | 3.95 | | 0.392 ± 0.074 |
| BPM | 346.19 | 9.47 | 7.04 | 0.98 | 0.444 ± 0.148 |
| BPP | 346.19 | 9.49 | 7.04 | | 0.451 ± 0.047 |
| BPAF | 336.06 | 8.90 | 5.02 | 1.10 | 0.522 ± 0.072 |
| BPAP | 290.13 | 9.36 | 5.00 | | 0.570 ± 0.062 |
| BP4-4 | 186.07 | 9.45 | 2.52 | | 0.663 ± 0.136 |
| BPE | 214.10 | 9.59 | 3.18 | 5.82 | 0.685 ± 0.158 |
| BPF | 200.08 | 9.66 | 2.91 | 7.58 | 0.696 ± 0.144 |
| 3-3BPA | 256.15 | 9.74 | 4.81 | | 0.722 ± 0.070 |
| BPA | 228.12 | 9.52 | 3.32 | 4.09 | 0.813 ± 0.063 |
| BPB | 242.13 | 9.49 | 4.44 | 3.21 | 0.842 ± 0.079 |

372

Table 3: Chemical properties of bisphenols and relationship with the clearance index.

^aChemDraw17.1 (Molecular Networks). ^bChemDraw17.1 (ChemPropPro). ^cThe BP-studied

374 placental transfer rate divided by the antipyrine transfer rate

376 The maternal plasma protein binding mechanism limits the rate of transfer across the placenta 377 because only the free fraction of a molecule can diffuse across a cell membrane. A recent study to 378 determine the affinities for human serum albumin of bisphenol A and several of its analogues, both 379 by in vitro biomimetic LC and in silico prediction, showed that the interaction was largely nonspecific and mainly lipophilicity-driven (Grumetto, 2019). The predicted limited unbound fractions of 380 381 BPM and BPAF (0.98 and 1.10%, respectively) compared to those of highly diffusible BPs (BPE: 382 5.82%, BPF: 7.58%, BPA: 4.09% and BPB: 3.21 %) are consistent with their differences in 383 placental transfer rate. By contrast, the materno-fetal transfer of BPS is very limited even though its 384 predicted free fraction in serum is relatively high (13.23 %).

385 Alternatively, the materno-fetal transfer of BPS and BPFL might be restricted by the activity of an 386 efflux transporter. Indeed, several ATP-dependent transporters including multi-drug resistant 387 proteins and organic anion transporter (OAT) proteins, predominantly expressed in the 388 syncytiotrophoblast, are involved in the efflux transport of a wide variety of xenobiotics and thereby 389 in protection of the fetus (Syme et al., 2004). They are known to transport BPs compounds (Jin and 390 Audus, 2005; Mørck et al., 2010) and their levels could be altered by bisphenols (Sieppi et al., 391 2016; Speidel et al., 2018). However, previous data showed that P-glycoprotein is not involved in 392 limiting the materno-fetal placental transfer of BPS (Grandin et al., 2019). Further investigation is 393 required to see if small structural changes in these analogues could influence the binding sites to 394 transporters and thus the mechanism of transplacental transfer.

395 *4. Conclusion*

In conclusion, this is the first study to compare the materno-fetal placental transport of fifteen BPs perfused simultaneously through the term placenta, using the human placental perfusion model. These newly-introduced bisphenols present a wide range of placental transfer rates despite their similar molecular structures. Passive diffusion was the main transport mechanism for seven BPs, BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA. By contrast, the placenta transfer rates for BPFL and BPS were very limited, and intermediate for BPBP, BPZ, BPC, BPM, BPP and BPAF suggesting that their passage across the placenta does not rely solely on weak diffusional 403 permeability but might involve active transport. However, the placental transfer efficiency of these 404 structurally related bisphenols, determined ex vivo, cannot be explained by their physico-chemical 405 properties alone. The data obtained for these fifteen bisphenols will be particularly useful for further 406 development of Quantitative Structure-Activity Relationships (QSARs) models to evaluate the 407 relative contributions of physicochemical, molecular and structural properties in the placental 408 transfer of bisphenols in placental process (Giaginis et al., 2009), and predict the placental 409 transport of this important class of emerging contaminants. This could lead to rapid screening and 410 subsequent discarding of endocrine-active BPA substitutes with a high fetal exposure potential.

412 Acknowledgments

413 The authors thank N. Deschamps for her assistance and involvement in placenta perfusion.

415 3. References

- Ala-Kokko, T.I., Myllynen, P., Vähäkangas, K., 2000. Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology. Int. J. Obstet. Anesth.
 9, 26–38. https://doi.org/10.1054/ijoa.1999.0312
- Audus, K.L., 1999. Controlling drug delivery across the placenta. Eur. J. Pharm. Sci. 8, 161–
 165. https://doi.org/10.1016/S0928-0987(99)00031-7
- 421 Caballero-Casero, N., Lunar, L., Rubio, S., 2016. Analytical methods for the determination of
 422 mixtures of bisphenols and derivatives in human and environmental exposure
 423 sources and biological fluids. A review. Anal. Chim. Acta 908, 22–53.
 424 https://doi.org/10.1016/j.aca.2015.12.034
- 425 Catanese, M.C., Vandenberg, L.N., 2016. Bisphenol S (BPS) alters maternal behavior and
 426 brain in mice exposed during pregnancy/lactation and their daughters. Endocrinology
 427 en.2016-1723. https://doi.org/10.1210/en.2016-1723
- 428 Ceckova-Novotna, M., Pavek, P., Staud, F., 2006. P-glycoprotein in the placenta:
 429 Expression, localization, regulation and function. Reprod. Toxicol. 22, 400–410.
 430 https://doi.org/10.1016/j.reprotox.2006.01.007
- Challier, J.-C., 1985. Criteria for Evaluating Perfusion Experiments and Presentation of
 Results, in: Schneider, H., Dancis, J. (Eds.), Contributions to Gynecology and
 Obstetrics. S. Karger AG, pp. 32–39. https://doi.org/10.1159/000410667
- Challier, J.C., D'Athis, Ph., Guerre-Millo, M., Nandakumaran, M., 1983. Flow-dependent
 transfer of antipyrine in the human placenta in vitro. Reprod. Nutr. Dév. 23, 41–50.
 https://doi.org/10.1051/rnd:19830104
- Chen, D., Kannan, K., Tan, H., Zheng, Z., Feng, Y.-L., Wu, Y., Widelka, M., 2016. Bisphenol
 Analogues Other Than BPA: Environmental Occurrence, Human Exposure, and
 Toxicity—A Review. Environ. Sci. Technol. 50, 5438–5453.
 https://doi.org/10.1021/acs.est.5b05387
- Chen, Y., Fang, J., Ren, L., Fan, R., Zhang, J., Liu, G., Zhou, L., Chen, D., Yu, Y., Lu, S.,
 2018. Urinary bisphenol analogues and triclosan in children from south China and
 implications for human exposure. Environ. Pollut. 238, 299–305.
 https://doi.org/10.1016/j.envpol.2018.03.031
- Corbel, T., Gayrard, V., Puel, S., Lacroix, M.Z., Berrebi, A., Gil, S., Viguié, C., Toutain, P.-L.,
 Picard-Hagen, N., 2014. Bidirectional placental transfer of Bisphenol A and its main
 metabolite, Bisphenol A-Glucuronide, in the isolated perfused human placenta.
 Reprod. Toxicol. 47, 51–58. https://doi.org/10.1016/j.reprotox.2014.06.001
- 449 European Medecines Agency, 2011. Guideline on bioanalytical method validation.
- Frederiksen, H., Nielsen, O., Koch, H.M., Skakkebaek, N.E., Juul, A., Jørgensen, N.,
 Andersson, A.-M., 2020. Changes in urinary excretion of phthalates, phthalate
 substitutes, bisphenols and other polychlorinated and phenolic substances in young
 Danish men; 2009–2017. Int. J. Hyg. Environ. Health 223, 93–105.
 https://doi.org/10.1016/j.ijheh.2019.10.002
- Gauderat, G., Picard-Hagen, N., Toutain, P.-L., Servien, R., Viguié, C., Puel, S., Lacroix,
 M.Z., Corbel, T., Bousquet-Melou, A., Gayrard, V., 2017. Prediction of human
 prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semiphysiological toxicokinetic model. Sci. Rep. 7. https://doi.org/10.1038/s41598-01715646-5
- Gavard, L., Beghin, D., Forestier, F., Cayre, Y., Peytavin, G., Mandelbrot, L., Farinotti, R.,
 Gil, S., 2009. Contribution and limit of the model of perfused cotyledon to the study of
 placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir. Eur. J.
 Obstet. Gynecol. Reprod. Biol. 147, 157–160.
 https://doi.org/10.1016/j.ejogrb.2009.08.007
- Gedeon, C., Koren, G., 2006. Designing Pregnancy Centered Medications: Drugs Which Do
 Not Cross the Human Placenta☆. Placenta 27, 861–868.
 https://doi.org/10.1016/j.placenta.2005.09.001

- Giaginis, C., Zira, A., Theocharis, S., Tsantili-Kakoulidou, A., 2009. Application of quantitative
 structure–activity relationships for modeling drug and chemical transport across the
 human placenta barrier: a multivariate data analysis approach. J. Appl. Toxicol. 29,
 724–733. https://doi.org/10.1002/jat.1466
- Gingrich, J., Pu, Y., Ehrhardt, R., Karthikraj, R., Kannan, K., Veiga-Lopez, A., 2019.
 Toxicokinetics of bisphenol A, bisphenol S, and bisphenol F in a pregnancy sheep
 model. Chemosphere 220, 185–194.
 https://doi.org/10.1016/j.chemosphere.2018.12.109
- 475 González, N., Cunha, S.C., Ferreira, R., Fernandes, J.O., Marquès, M., Nadal, M., Domingo,
- J.L., 2020. Concentrations of nine bisphenol analogues in food purchased from
 Catalonia (Spain): Comparison of canned and non-canned foodstuffs. Food Chem.
 Toxicol. 136, 110992. https://doi.org/10.1016/j.fct.2019.110992
- 480 Grandin, F., Picard-Hagen, N., Gayrard, V., Puel, S., Viguié, C., Toutain, P.-L., Debrauwer, 481 L., Lacroix, M.Z., 2017. Development of an on-line solid phase extraction ultra-high-482 performance liquid chromatography technique coupled to tandem mass spectrometry 483 for quantification of bisphenol S and bisphenol S glucuronide: Applicability to 484 toxicokinetic investigations. Chromatogr. 39–46. J. А 1526, 485 https://doi.org/10.1016/j.chroma.2017.10.020
- 486 Grandin, F.C., Lacroix, M.Z., Gayrard, V., Gauderat, G., Mila, H., Toutain, P.-L., Picard487 Hagen, N., 2018. Bisphenol S instead of Bisphenol A: Toxicokinetic investigations in
 488 the ovine materno-feto-placental unit. Environ. Int. 120, 584–592.
 489 https://doi.org/10.1016/j.envint.2018.08.019
- Grandin, F.C., Lacroix, M.Z., Gayrard, V., Viguié, C., Mila, H., de Place, A., Vayssière, C.,
 Morin, M., Corbett, J., Gayrard, C., Gely, C.A., Toutain, P.-L., Picard-Hagen, N.,
 2019. Is bisphenol S a safer alternative to bisphenol A in terms of potential fetal
 exposure ? Placental transfer across the perfused human placenta. Chemosphere
 221, 471–478. https://doi.org/10.1016/j.chemosphere.2019.01.065
- Grumetto, L., 2019. Scrutinizing the interactions between bisphenol analogues and plasma
 proteins_ Insights from biomimetic liquid chromatography, molecular docking
 simulations and in silico predictions. Environ. Toxicol. Pharmacol. 7.
- Gyllenhammar, I., Glynn, A., Jönsson, B.A.G., Lindh, C.H., Darnerud, P.O., Svensson, K.,
 Lignell, S., 2017. Diverging temporal trends of human exposure to bisphenols and
 plastizisers, such as phthalates, caused by substitution of legacy EDCs? Environ.
 Res. 153, 48–54. https://doi.org/10.1016/j.envres.2016.11.012
- Husøy, T., Andreassen, M., Hjertholm, H., Carlsen, M.H., Norberg, N., Sprong, C.,
 Papadopoulou, E., Sakhi, A.K., Sabaredzovic, A., Dirven, H.A.A.M., 2019. The
 Norwegian biomonitoring study from the EU project EuroMix: Levels of phenols and
 phthalates in 24-hour urine samples and exposure sources from food and personal
 care products. Environ. Int. 132, 105103. https://doi.org/10.1016/j.envint.2019.105103
- Hutson, J.R., Garcia-Bournissen, F., Davis, A., Koren, G., 2011. The Human Placental
 Perfusion Model: A Systematic Review and Development of a Model to Predict In
 Vivo Transfer of Therapeutic Drugs. Clin. Pharmacol. Ther. 90, 67–76.
 https://doi.org/10.1038/clpt.2011.66
- Ihde, E.S., Zamudio, S., Loh, J.M., Zhu, Y., Woytanowski, J., Rosen, L., Liu, M., Buckley, B.,
 2018. Application of a novel mass spectrometric (MS) method to examine exposure
 to Bisphenol-A and common substitutes in a maternal fetal cohort. Hum. Ecol. Risk
 Assess. Int. J. 24, 331–346. https://doi.org/10.1080/10807039.2017.1381831
- 515Jin, H., Audus, K.L., 2005. Effect of bisphenol A on drug efflux in BeWo, a human516trophoblast-likecellline.Placenta26,S96–S103.517https://doi.org/10.1016/j.placenta.2005.01.016
- Joshi, A.A., Vaidya, S.S., St-Pierre, M.V., Mikheev, A.M., Desino, K.E., Nyandege, A.N.,
 Audus, K.L., Unadkat, J.D., Gerk, P.M., 2016. Placental ABC Transporters: Biological
 Impact and Pharmaceutical Significance. Pharm. Res. 33, 2847–2878.
 https://doi.org/10.1007/s11095-016-2028-8

- Karttunen, V., Sahlman, H., Repo, J.K., Woo, C.S.J., Myöhänen, K., Myllynen, P.,
 Vähäkangas, K.H., 2015. Criteria and challenges of the human placental perfusion –
 Data from a large series of perfusions. Toxicol. In Vitro 29, 1482–1491.
 https://doi.org/10.1016/j.tiv.2015.06.001
- Kojima, H., Takeuchi, S., Sanoh, S., Okuda, K., Kitamura, S., Uramaru, N., Sugihara, K.,
 Yoshinari, K., 2019. Profiling of bisphenol A and eight its analogues on transcriptional activity T via human nuclear receptors 8.
- Lacroix, M.Z., Puel, S., Collet, S.H., Corbel, T., Picard-Hagen, N., Toutain, Pl., Viguié, C.,
 Gayrard, V., 2011. Simultaneous quantification of bisphenol A and its glucuronide
 metabolite (BPA-G) in plasma and urine: Applicability to toxicokinetic investigations.
 Talanta 85, 2053–2059. https://doi.org/10.1016/j.talanta.2011.07.040
- Larsson, A., Palm, M., Hansson, L.-O., Axelsson, O., 2008. Reference values for clinical
 chemistry tests during normal pregnancy. BJOG Int. J. Obstet. Gynaecol. 115, 874–
 881. https://doi.org/10.1111/j.1471-0528.2008.01709.x
- Lehmler, H.-J., Liu, B., Gadogbe, M., Bao, W., 2018. Exposure to Bisphenol A, Bisphenol F,
 and Bisphenol S in U.S. Adults and Children: The National Health and Nutrition
 Examination Survey 2013–2014. ACS Omega 3, 6523–6532.
 https://doi.org/10.1021/acsomega.8b00824
- Liao, C., Kannan, K., 2014. A Survey of Alkylphenols, Bisphenols, and Triclosan in Personal
 Care Products from China and the United States. Arch. Environ. Contam. Toxicol. 67,
 50–59. https://doi.org/10.1007/s00244-014-0016-8
- Liao, C., Kannan, K., 2013. Concentrations and Profiles of Bisphenol A and Other Bisphenol
 Analogues in Foodstuffs from the United States and Their Implications for Human
 Exposure. J. Agric. Food Chem. 61, 4655–4662. https://doi.org/10.1021/jf400445n
- Liu, J., Li, J., Wu, Y., Zhao, Y., Luo, F., Li, S., Yang, L., Moez, E.K., Dinu, I., Martin, J.W.,
 2017. Bisphenol A Metabolites and Bisphenol S in Paired Maternal and Cord Serum.
 Environ. Sci. Technol. 51, 2456–2463. https://doi.org/10.1021/acs.est.6b05718
- Lucarini, F., Krasniqi, T., Bailat Rosset, G., Roth, N., Hopf, N.B., Broillet, M.-C., Staedler, D.,
 2020. Exposure to New Emerging Bisphenols Among Young Children in Switzerland.
 Int. J. Environ. Res. Public. Health 17, 4793. https://doi.org/10.3390/ijerph17134793
- 552 Luo, H., Li, C., Fang, H., Wang, X., 2016. Comparative study of the interactions between 553 bisphenol analogues and serum albumins by electrospray mass spectrometry and 554 fluorescence spectroscopy: Interactions between bisphenol analogues and serum Mass 555 albumins. Rapid Commun. Spectrom. 30, 162–167. 556 https://doi.org/10.1002/rcm.7633
- Mørck, T.J., Sorda, G., Bechi, N., Rasmussen, B.S., Nielsen, J.B., letta, F., Rytting, E.,
 Mathiesen, L., Paulesu, L., Knudsen, L.E., 2010. Placental transport and in vitro
 effects of Bisphenol A. Reprod. Toxicol. 30, 131–137.
 https://doi.org/10.1016/j.reprotox.2010.02.007
- Moreman, J., Lee, O., Trznadel, M., David, A., Kudoh, T., Tyler, C.R., 2017. Acute Toxicity,
 Teratogenic, and Estrogenic Effects of Bisphenol A and Its Alternative Replacements
 Bisphenol S, Bisphenol F, and Bisphenol AF in Zebrafish Embryo-Larvae. Environ.
 Sci. Technol. 51, 12796–12805. https://doi.org/10.1021/acs.est.7b03283
- Mustieles, V., D'Cruz, S.C., Couderq, S., Rodríguez-Carrillo, A., Fini, J.-B., Hofer, T.,
 Steffensen, I.-L., Dirven, H., Barouki, R., Olea, N., Fernández, M.F., David, A., 2020.
 Bisphenol A and its analogues: A comprehensive review to identify and prioritize
 effect biomarkers for human biomonitoring. Environ. Int. 144, 105811.
 https://doi.org/10.1016/j.envint.2020.105811
- 570 Pacifici, G.M., Nottoli, R., 1995. Placental Transfer of Drugs Administered to the Mother: Clin. 571 Pharmacokinet. 28, 235–269. https://doi.org/10.2165/00003088-199528030-00005
- Pan, Y., Deng, M., Li, J., Du, B., Lan, S., Liang, X., Zeng, L., 2020. Occurrence and Maternal Transfer of Multiple Bisphenols, Including an Emerging Derivative with Unexpectedly High Concentrations, in the Human Maternal–Fetal–Placental Unit. Environ. Sci. Technol. 54, 3476–3486. https://doi.org/10.1021/acs.est.0c00206

- Pelch, K., Wignall, J.A., Goldstone, A.E., Ross, P.K., Blain, R.B., Shapiro, A.J., Holmgren,
 S.D., Hsieh, J.-H., Svoboda, D., Auerbach, S.S., Parham, F.M., Masten, S.A., Walker,
 V., Rooney, A., Thayer, K.A., 2019. A scoping review of the health and toxicological
 activity of bisphenol A (BPA) structural analogues and functional alternatives.
 Toxicology 424, 152235. https://doi.org/10.1016/j.tox.2019.06.006
- Philips, E.M., Kahn, L.G., Jaddoe, V.W.V., Shao, Y., Asimakopoulos, A.G., Kannan, K.,
 Steegers, E.A.P., Trasande, L., 2018. First Trimester Urinary Bisphenol and
 Phthalate Concentrations and Time to Pregnancy: A Population-Based Cohort
 Analysis. J. Clin. Endocrinol. Metab. 103, 3540–3547. https://doi.org/10.1210/jc.201800855
- Rochester, J.R., Bolden, A.L., 2015. Bisphenol S and F: A Systematic Review and
 Comparison of the Hormonal Activity of Bisphenol A Substitutes. Environ. Health
 Perspect. https://doi.org/10.1289/ehp.1408989
- Rosenmai, A.K., Dybdahl, M., Pedersen, M., Alice van Vugt-Lussenburg, B.M., Wedebye,
 E.B., Taxvig, C., Vinggaard, A.M., 2014. Are Structural Analogues to Bisphenol A
 Safe Alternatives? Toxicol. Sci. 139, 35–47. https://doi.org/10.1093/toxsci/kfu030
- Schneider, H., Panigel, M., Dancis, J., 1972. Transfer across the perfused human placenta of
 antipyrine, sodium, and leucine. Am. J. Obstet. Gynecol. 114, 822–828.
 https://doi.org/10.1016/0002-9378(72)90909-X
- 595 Search for Chemicals ECHA [WWW Document], n.d. URL https://echa.europa.eu/fr/search-596 for-
- 597chemicals?p_p_id=disssimplesearch_WAR_disssearchportlet&p_p_lifecycle=0&_diss598simplesearch_WAR_disssearchportlet_searchOccurred=true&_disssimplesearch_WA599R_disssearchportlet_sessionCriteriald=dissSimpleSearchSessionParam101401602560081767544 (accessed 10.13.20).
- Shi, M., Sekulovski, N., MacLean, J.A., Hayashi, K., 2018. Prenatal Exposure to Bisphenol A
 Analogues on Male Reproductive Functions in Mice. Toxicol. Sci. 163, 620–631.
 https://doi.org/10.1093/toxsci/kfy061
- Sieppi, E., Vähäkangas, K., Rautio, A., letta, F., Paulesu, L., Myllynen, P., 2016. The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures. Mol. Cell.
 Endocrinol. 429, 41–49. https://doi.org/10.1016/j.mce.2016.03.034
- Siracusa, J.S., Yin, L., Measel, E., Liang, S., Yu, X., 2018. Effects of bisphenol A and its
 analogs on reproductive health: A mini review. Reprod. Toxicol. 79, 96–123.
 https://doi.org/10.1016/j.reprotox.2018.06.005
- Speidel, J.T., Xu, M., Abdel-Rahman, S.Z., 2018. Bisphenol A (BPA) and bisphenol S (BPS)
 alter the promoter activity of the ABCB1 gene encoding P-glycoprotein in the human
 placenta in a haplotype-dependent manner. Toxicol. Appl. Pharmacol. 359, 47–54.
 https://doi.org/10.1016/j.taap.2018.09.022
- Syme, M.R., Paxton, J.W., Keelan, J.A., 2004. Drug Transfer and Metabolism by the Human
 Placenta: Clin. Pharmacokinet. 43, 487–514. https://doi.org/10.2165/00003088200443080-00001
- Tucker, D.K., Hayes Bouknight, S., Brar, S.S., Kissling, G.E., Fenton, S.E., 2018. Evaluation
 of Prenatal Exposure to Bisphenol Analogues on Development and Long-Term
 Health of the Mammary Gland in Female Mice. Environ. Health Perspect. 126,
 087003. https://doi.org/10.1289/EHP3189
- Usman, A., Ahmad, M., 2016. From BPA to its analogues: Is it a safe journey? Chemosphere
 158, 131–142. https://doi.org/10.1016/j.chemosphere.2016.05.070
- Wang, Y.-Q., Zhang, H.-M., Cao, J., Tang, B.-P., 2014. Binding of a new bisphenol analogue,
 bisphenol S to bovine serum albumin and calf thymus DNA. J. Photochem. Photobiol.
 B 138, 182–190. https://doi.org/10.1016/j.jphotobiol.2014.06.002
- Yang, H., Huang, Y., Liu, J., Tang, P., Sun, Q., Xiong, X., Tang, B., He, J., Li, H., 2017.
 Binding modes of environmental endocrine disruptors to human serum albumin: insights from STD-NMR, ITC, spectroscopic and molecular docking studies. Sci. Rep. 7, 11126. https://doi.org/10.1038/s41598-017-11604-3

- Yang, Yunjia, Lu, L., Zhang, J., Yang, Yi, Wu, Y., Shao, B., 2014. Simultaneous determination of seven bisphenols in environmental water and solid samples by liquid chromatography–electrospray tandem mass spectrometry. J. Chromatogr. A 1328, 26–34. https://doi.org/10.1016/j.chroma.2013.12.074
- Ye, X., Wong, L.-Y., Kramer, J., Zhou, X., Jia, T., Calafat, A.M., 2015. Urinary
 Concentrations of Bisphenol A and Three Other Bisphenols in Convenience Samples
 of U.S. Adults during 2000–2014. Environ. Sci. Technol. 49, 11834–11839.
 https://doi.org/10.1021/acs.est.5b02135
- Zhang, B., He, Y., Zhu, H., Huang, X., Bai, X., Kannan, K., Zhang, T., 2020. Concentrations
 of bisphenol A and its alternatives in paired maternal–fetal urine, serum and amniotic
 fluid from an e-waste dismantling area in China. Environ. Int. 136, 105407.
 https://doi.org/10.1016/j.envint.2019.105407
- Zhang, Y.-F., Ren, X.-M., Li, Y.-Y., Yao, X.-F., Li, C.-H., Qin, Z.-F., Guo, L.-H., 2018.
 Bisphenol A alternatives bisphenol S and bisphenol F interfere with thyroid hormone
 signaling pathway in vitro and in vivo. Environ. Pollut. 237, 1072–1079.
 https://doi.org/10.1016/j.envpol.2017.11.027
- 648
- 649 Figure legends
- 650 Figure 1: Molecular structures of the fifteen BPs
- Figure 2: Clearance indices of the 15 BPs (individual values (x) and mean ± SD), corresponding to
- the ratio of the transfer rate of each bisphenol to that of antipyrine.
- 653



Placental transfer efficiencies

Created with BioRender.com